🔗 Share this article WHO Raises Alert Over Acute Lack of Weight-Loss Injections Less than one in 10 people that would benefit from obesity jabs such as Wegovy can access them, caution the WHO as it issues its inaugural guidance on the therapies. Given more than one billion individuals worldwide now classified as obese, it is calling for increased and just access to these injectable treatments. Based on projections, more than two billion could be obese by 2030 if no action is taken. "The latest guidance recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key hurdles to universal access to the injections that can assist patients in reducing significant body mass, notes the body. Skinny Jab Scarcity Even in the present most favorable outlook, the supply of these medications could only cover about 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The guideline encourages governments and firms to widen availability, by measures such as voluntary licensing. Exclusive production rights on a key compound – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Jabs Work GLP-1 drugs imitate a body's own hormone to reduce digestion speed, curb appetite and enhance the sense of being full so individuals consume fewer calories. Individuals typically start to lose weight within a few weeks of starting on the regular doses. Research indicates people may see weight return a year later of stopping the drug, as their usual food cravings come back. To be carrying excess weight elevates your risk for experiencing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies. Excess weight affects individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the WHO.
Less than one in 10 people that would benefit from obesity jabs such as Wegovy can access them, caution the WHO as it issues its inaugural guidance on the therapies. Given more than one billion individuals worldwide now classified as obese, it is calling for increased and just access to these injectable treatments. Based on projections, more than two billion could be obese by 2030 if no action is taken. "The latest guidance recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key hurdles to universal access to the injections that can assist patients in reducing significant body mass, notes the body. Skinny Jab Scarcity Even in the present most favorable outlook, the supply of these medications could only cover about 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The guideline encourages governments and firms to widen availability, by measures such as voluntary licensing. Exclusive production rights on a key compound – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Jabs Work GLP-1 drugs imitate a body's own hormone to reduce digestion speed, curb appetite and enhance the sense of being full so individuals consume fewer calories. Individuals typically start to lose weight within a few weeks of starting on the regular doses. Research indicates people may see weight return a year later of stopping the drug, as their usual food cravings come back. To be carrying excess weight elevates your risk for experiencing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies. Excess weight affects individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the WHO.